What is the segmentation of the global Systemic lupus erythematosus Treatment Market?
Global Systemic Lupus Erythematosus Treatment Market Research Report: By Treatment (Corticosteroids, Nonsteroidal anti-inflammatory drugs, Antimalarials, Immunosuppressive agents and immune modulators), By Route of Administration (Oral, Intravenous, Subcutaneous) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Forecast to 2027
Systemic lupus erythematosus (SLE), a type of lupus, is a chronic autoimmune disease which is characterized by fatigue and chronic pain. The suppressed immune system in this condition requires immune boosters and may be vulnerable to the COVID-19 virus. The global systemic lupus erythematosus treatment market report by Market Research Future (MRFR) has been collated using a combination of primary and secondary research and contains projections and insights for the period of 2019 to 2025 (forecast period). The impact of the COVID-19 pandemic and its effects has been noted in the report.
Market Scope
The global systemic lupus erythematosus treatment market is expected to cross USD 1.5 billion by 2025. It can expand at a CAGR of 6% over the forecast period.
Development of biologics for treatment of autoimmune diseases is projected to drive market growth. Clinical trials conducted for new drugs and investments in research and development by pharmaceutical companies can facilitate this trend. Approval of these drugs by federal regulatory bodies to alleviate pain levels can bode well for the market. This is exemplified by the approval of Benlysta and its efficacy in patients with moderate to severe degrees of SLE.
But adverse effects of medication and regulatory hurdles can restrain market growth.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8500
Segmentation
By treatment, it is segmented into immunosuppressive agents and immune modulators, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antimalarials.
Corticosteroids: SLE treatment involves the use of corticosteroids, which inhibits the immune system from attacking the healthy cells of the body. Prednisone is the most frequently prescribed corticosteroid for the treatment of systemic lupus erythematosus.
Nonsteroidal anti-inflammatory drugs (NSAIDs): This class of drugs decreases pain, reduces fever, and decreases inflammation. In around 80% of the cases, systemic lupus erythematosus medication involves the use of Nonsteroidal anti-inflammatory drugs (NSAIDs).
Antimalarials: Although initially antimalarials were used to treat malaria, it was later found that these drugs help reduce joint and muscle pain, inflammation of the lining of the lungs and heart, fatigue, and other symptoms of lupus. New drug approvals are expected to drive the growth of this segment. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for its generic version of antimalarial Plaquenil.
Immunosuppressive agents and immune modulators can be used to suppress the overactive immune response. The increasing demand for these drugs is expected to drive the segment growth. For instance, the sales of ballista (an immunosuppressant drug) increased by 24% in the US in 2018 as compared to 2017.
By route of administration, it is segmented into subcutaneous, intravenous, and oral.
The oral segment involves the administration of tablets and capsules for the treatment of systemic lupus erythematosus. It can remain the most trusted treatment method for treatment of SLE. On the other hand, the intravenous segment contains the use of drugs administered via veins of the patient. It has latent potential and shown better efficacy compared to the oral route.
By distribution channel, it is segmented into retail, hospital, and online pharmacies. Hospital pharmacies are expected to maintain the lead in the market due to an increase in the number of hospitals, followed by retail pharmacies. On the flip side, online pharmacies can exhibit the fastest growth rate during the forecast period due to increasing awareness of ecommerce and the trend of purchase of medicines online.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/systemic-lupus-erythematosus-treatment-market-8500
Regional Analysis
The Americas held the largest market share due to high healthcare expenditure and the presence of key market players. Access to biologics, medical reimbursement schemes, and presence of modern healthcare infrastructure can spur the regional market growth of systemic lupus erythematosus treatment.
Europe is the second-largest regional market due to increasing investments in research and measures taken for SLE management. APAC is the fastest-growing regional market due to increasing awareness regarding systemic lupus erythematosus treatment and a large patient pool affected by SLE.
Competitive Outlook
Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc, Sanofi, Johnson & Johnson Services, Inc., Anthera, and Novartis AG are key players of the global systemic lupus erythematosus treatment market.
You may also be interested in..
Migraine with Brainstem Aura Market Research Report – Forecast to 2023
Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report – Forecast to 2023
Mouth Ulcer Treatment Market Research Report – Forecast to 2023
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
